Navigation Links
FDA Halts New Applications From Indian Drug Maker's Plant
Date:2/25/2009

Agency says Ranbaxy Laboratories facility falsified scientific data

WEDNESDAY, Feb. 25 (HealthDay News) -- U.S. health officials have halted the review of any new drug applications from a Ranbaxy Laboratories plant in India after determining the facility was falsifying scientific data.

Ranbaxy, based in India, is one of the largest suppliers of generic drugs to the United States.

"We took this action after it became apparent that this facility was submitting falsified scientific data in applications for FDA approval of marketed drugs in the United States," Dr. Douglas Throckmorton, deputy director of FDA's Center for Drug Evaluation and Research, said during a Wednesday teleconference.

Falsifying data in drug applications is a "serious breach of integrity -- a breach that must be quickly addressed and corrected," Throckmorton added.

Throckmorton noted this is the second action against the Paonta Sahib facility in less than six months. "No other Ranbaxy facilities are directly affected by this action," he said.

Until these problems are resolved, the FDA will stop review of drug applications from the Paonta Sahib plant and the agency will not accept any new applications from this plant, Throckmorton said.

These applications fall into three categories, drugs made in the plant for the U.S. market, drugs not marketed in the United States pending FDA approval, and drugs made in the United States that relied on data from the Paonta Sahib plant.

Last September, the FDA denied U.S. entry of 30 generic drugs made at the Paonta Sahib plant and a sister facility in Dewas, India, for problems related to the manufacturing process. At that time, FDA officials also recommended denying any new drug applications from those two plants.

Some of the false data supplied from the Paonta Sahib plant involved the shelf life of products, Deborah Autor, director of the FDA's Office of Compliance at the Center for Drug Evaluation and Research, said during the teleconference. In addition, the company falsified data about production practices, she said.

The agency will begin reviewing applications only after Ranbaxy is able to prove to the agency that all of its data are correct and the FDA no longer has a concern about the data in the applications, Autor said.

While most products made by the company in the United States are not part of the FDA action, Autor added, there are some U.S. products that are affected.

Two of them are cholesterol-lowering drugs, pravastatin (Pravachol) and imvastatin (simvastatin), and an antihistamine known as pheniramine (Avil), Autor said.

The FDA is asking Ranbaxy for assurance that none of the data on these drug applications are from the Paonta Sahib facility, she explained.

Throckmorton was careful to say that the FDA has received no reports of harm caused by Ranbaxy products made in the United States or in the Paonta Sahib plant.

In addition, the agency is advising patients not to stop taking any medications without talking with their doctors first, he said.

More information

For more information on drug safety, visit the U.S. Food and Drug Administration .



SOURCES: Feb. 25, 2009, teleconference with: Douglas Throckmorton, M.D., deputy director, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, and Deborah Autor, J.D., director, Office of Compliance, Center for Drug Evaluation and Research, FDA


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Kellogg Halts Sales of Peanut Butter Crackers
2. Gastric Bypass Halts Diabetes in Obese Teens
3. PA Department of Health Halts Admissions at Commonwealth Medical Center in Beaver County
4. Surgical technique halts cell loss, Parkinsons researchers find
5. St. Jude finds signaling system that halts the growth of a childhood brain cancer
6. Manufacturer Halts Production of Blood Thinner Heparin
7. Experimental Vaccine Halts Prostate Cancer in Mice
8. Scripps research scientists find new genetic mutation that halts the development of lupus
9. Photo: New Data Show Gleevec(R) Halts Progression to Advanced Stages of Life-Threatening Form of Leukemia in Sixth Year of Treatment
10. Nephros Provides Update on 510k Applications
11. IMRIS announces development program for MR guided radiation and interventional applications
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Halts New Applications From Indian Drug Maker's Plant
(Date:2/8/2016)... ... 2016 , ... The Bell Agency, a full service insurance ... their ongoing community enrichment program. The current campaign fundraises for Angels & Doves, ... being accepted at: http://www.angelsanddoves.com/donate.html . , Angels & Doves was founded in ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... ... that co-occur frequently. While a significant number of women and men with eating ... the trauma itself, that best predicts the development of an eating disorder. ...
(Date:2/8/2016)... KS (PRWEB) , ... February 08, 2016 , ... TopConsumerReviews.com ... leader in Mole removal products. , Moles are derived from a cluster of melanin ... in all the wrong places and create a lifetime of embarrassment. Historically, mole ...
(Date:2/7/2016)... (PRWEB) , ... February 07, 2016 , ... ... prolapse with the latest techniques and the most minimally invasive approaches. , Women ... prolapse, particularly after menopause. Other risk factors include surgery to the pelvic floor, ...
(Date:2/6/2016)... , ... February 06, 2016 , ... US Sports Camps ... Conference (YUCC) . This event brings together top non-profit leaders, ultimate organizations, and coaches ... Girls Ultimateā€. Valerio Iani, Bay Area Disc Program Director of Youth and Education, describes ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... Feb. 8, 2016  Neurocrine Biosciences, Inc. (Nasdaq: ... its fourth quarter and year-end 2015 results after the ... will then host a live conference call and webcast ... update Thursday afternoon, February 11, 2016 at 4:30 p.m. ... . --> http://www.neurocrine.com . --> ...
(Date:2/8/2016)... LAWRENCEVILLE, N.J. , Feb. 8, 2016   ... for healthcare professionals to guide them through GS1 Standards ... and Drug Administration (FDA) Unique Device Identification (UDI) rule. ... standards, GS1 US; Beth Gibson , senior director ... Roberts , industry development director, GS1 US ...
(Date:2/8/2016)... 8, 2016   HighPoint Solutions today ... (NRG),s pharmacovigilance technology services division.  NRG is a ... an Oracle Argus Specialized partner, providing drug safety ... companies. --> --> ... sciences capabilities and provides a global scale and ...
Breaking Medicine Technology: